Leukemia, Myelodysplasia, Transplantation
Video
Triple Therapy for CLL
News
Study shows imatinib response is durable and improves with time
SAN FRANCISCO—The longest duration study of imatinib treatment for patients with Ph+ CML shows 86% of patients are still alive 7 years after...